Filing Details
- Accession Number:
- 0001415889-25-001007
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-01-07 16:43:44
- Reporting Period:
- 2024-12-13
- Accepted Time:
- 2025-01-07 16:43:44
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1672619 | Enliven Therapeutics Inc. | ELVN | Pharmaceutical Preparations (2834) | 811523849 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1882764 | Benjamin Hohl | C/O Enliven Therapeutics, Inc. 6200 Lookout Road Boulder CO 80301 | Chief Financial Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-12-13 | 13,000 | $2.48 | 13,000 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2025-01-03 | 1,000 | $2.48 | 14,000 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2025-01-03 | 1,000 | $25.04 | 13,000 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2024-12-13 | 13,000 | $0.00 | 13,000 | $2.48 |
| Common Stock | Stock Option (right to buy) | Disposition | 2025-01-03 | 1,000 | $0.00 | 1,000 | $2.48 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 155,556 | 2031-08-02 | No | 4 | M | Direct | |
| 150,306 | 2031-08-02 | No | 4 | M | Direct |
Footnotes
- The 1,000 share option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023.
- This transaction was executed in multiple trades at prices ranging from $25.00 to $25.045. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- The option, originally for 262,120 shares, vested as to one-fourth of the shares on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter.
- The number of derivative securities beneficially owned following the option exercise was as of December 13, 2024 and does not reflect subsequent option exercises that occurred on December 27, 2024 and December 30, 2024 as reported in a Form 4 filed by the Reporting Person on December 31, 2024.
- The number of derivative securities beneficially owned following the option exercise is as of January 3, 2025 and reflects the option exercise that occurred December 13, 2024, and reported herein, and subsequent option exercises that occurred on December 27, 2024 and December 30, 2024 as reported in a Form 4 filed by the Reporting Person on December 31, 2024
Billionaire Hedge Funds
